VENDOR · GLOBAL
AstraZeneca commits up to $1.5B to Insitro for AI-driven drug discovery platform
Pharma giant AstraZeneca signed deal with AI drug-discovery startup Insitro for up to $1.5B (upfront + milestones). Insitro uses machine learning to accelerate preclinical and clinical research pipelines.
WHY IT MATTERS
Largest biotech AI partnership to date validates commercial model for foundation models in drug discovery. Signals pharma R&D budget shift from headcount to AI platforms; creates new data-moat competition.
Source: WSJ · 2026-10-17